The company will provide a corporate update to the investment community and shareholders through a YouTube livestream video on today at 10:00am EST.
The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.
The YouTube livestream video will be available through livestream.innocanpharma.com
Hub On AGORACOM / Read Recent Release…
Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD
- Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
- Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
- Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
- Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
- Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.
Tags: Axim Biotechnologies, biopharma, Cardiol Therapeutics Inc, CBD stocks, CSE, CURE Pharmaceutical Holding Corp, InMed Pharmaceuticals Inc., Innocan, MediPharm Labs Corp, Relief & Go Pain Relief Spray, small cap, smallcap stocks, stocks